Fernand Labrie
Publications
Page 5 of 8, showing 50 records out of 368 total, starting on record 201, ending on 250
| Publication | Category | Year |
|---|---|---|
| 203. Dupont, A., Labrie, F., Giguere, M., Borsanyi, J.-P., Lacourcière, Y., Bergeron, N., Cusan, L., Bélanger, A., Emond, J. (1988) Combination therapy with Flutamide and [D-Trp6]LHRH ethylamide for stage C prostatic carcinoma. Eur. J. Cancer Oncol., 24: 659-666. | Prostate Cancer | 1988 |
| 204. Dupont, A., Labrie, F., Giguère, M., Borsanyi, J.-P., Lacourcière, Y., Bélanger, A., Lachance, R., Emond, J., Monfette, G. (1988) Combination therapy with Flutamide and castration (orchiectomy or LHRH agonist) in untreated patients with advanced prostate cancer, in: Höffken, K., ed. LHRH agonists in Oncology. Symposium on GnRH Analogues, Essen, pp 60-71. | Prostate Cancer | 1988 |
| 205. Labrie, C., Bélanger, A., Labrie, F. (1988) Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology, 123: 1412-1417. | Prostate Cancer | 1988 |
| 206. Labrie, F., Bélanger, A., Veilleux, R., Lacoste, D., Labrie, C., Marchetti, B., Poulin, R., Dupont, A., Cusan, L., Luthy, I. (1988) Rationale for maximal androgen withdrawal in the therapy of prostate cancer, in: Furr, M. et Denis, L., eds: Baillieres Clinics in Oncology on Prostate Cancer, London, Saunders Company, pp 597-619. | Prostate Cancer | 1988 |
| 207. Labrie, F., Dupont, A., Bélanger, A., Simard, J., Labrie, C., Poulin, R., Luthy, I., Veilleux, R., Lacoste, D., Marchetti, B., Cusan, L., Manhès, G., Monfette, G., Emond, J. (1988) Combination therapy with the antiandrogen Flutamide and the LHRH agonist [D-Trp6,des-Gly-NH210]LHRH ethylamide in prostate cancer: rationale and 5-year clinical experience, in: Chretien, M. et McKerns, K.W., eds: Molecular Biology of Brain and Endocrine Peptidergic Systems, New York, Plenum Press, pp 83-101. | Prostate Cancer | 1988 |
| 208. Labrie, F., Dupont, A., Cusan, L., Bélanger, A., Giguère, M., Labrie, C., Lacourcière, Y., Monfette, G., Emond, J. (1988) Combination therapy with Flutamide and [D-Trp6, des-Gly-NH210]LHRH ethylamide in stage C and D prostate cancer: Today's therapy of choice - Rationale and 5-year clinical experience. Prog. Clin. Biol. Res., 262: 11-63. | Prostate Cancer | 1988 |
| 209. Labrie, F., Dupont, A., Cusan, L., Giguère, M., Bergeron, N., Borsanyi, J.P., Lacourcière, Y., Bélanger, A., Emond, J., Monfette, G., Boucher, H., Lachance, R. (1988) Combination therapy with Flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice. J. Steroid Biochem., 30: 107-117. | Prostate Cancer | 1988 |
| 210. Labrie, F., Dupont, A., Cusan, L., Giguère, M., Bergeron, N., Lacourcière, Y., Bélanger, A., Monfette, G., Emond, J. (1988) Combination therapy with Flutamide and [D-Trp6]LHRH ethylamide in advanced (stages C and D) previously untreated prostate cancer, in: Motta, M. et Serio, M., eds: Hormonal therapy of prostatic diseases: basic and clinical aspects: International Symposium, Milano, Italy, April 6-8 1987: abstracts of lectures and free communications, pp 312-333. | Prostate Cancer | 1988 |
| 211. Labrie, F., Dupont, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Bélanger, A., Lachance, R., Emond, J., Monfette, G. (1988) Combination therapy with Flutamide and castration (orchiectomy of LHRH agonists): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer. Review Article. Prog. Clin. Biol. Res., 260: 41-62. | Prostate Cancer | 1988 |
| 212. Labrie, F., Dupont, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Monfette, G., Emond, J., Bergeron, N. (1988) Benefits of combination therapy with Flutamide in patients relapsing after castration. Br. J. Urol., 61: 341-346. | Prostate Cancer | 1988 |
| 213. Labrie, F., Dupont, A., Giguère, M., Cusan, L., Bergeron, N., Emond, J., Monfette, G., Lacourcière, Y., Boucher, H., Lachance, R. (1988) Important prognostic value of standardized objective criteria of response in stage D2 prostatic carcinoma. Eur. J. Cancer Clin. Oncol., 24: 1869-1878. | Prostate Cancer | 1988 |
| 214. Labrie, F., Veilleux, R., Fournier, A. (1988) Low androgen levels induce the development of androgen hypersensitive cell clones in Shionogi mouse mammary carcinoma cells in culture. J. Natl. Cancer Inst., 80: 1138-1147. | Prostate Cancer | 1988 |
| 215. Labrie, F., Veilleux, R., Fournier, A. (1988) Maintenance of androgen responsiveness by glucocorticoids in Shionogi mammary carcinoma cells in culture. J. Natl. Cancer Inst., 80: 966-970. | Prostate Cancer | 1988 |
| 216. Lacoste, D., St-Arnaud, R., Bélanger, A., Labrie, F. (1988) A pure antiandrogen does not interfere with the LHRH agonist-induced blockade of testicular androgen secretion in the dog. Mol. Cell. Endocrinol., 56: 141-147. | Prostate Cancer | 1988 |
| 217. Lacoste, D., St-Arnaud, R., Caron, S., Bélanger, A., Labrie, F. (1988) The rise in testicular androgens during the first days of treatment with an LHRH agonist in the dog can be blocked by aminoglutethimide or ketoconazole. J. Steroid Biochem., 31: 963-970. | Prostate Cancer | 1988 |
| 218. Luthy, I., Bégin, D., Labrie, F. (1988) Mediation by the androgen receptor of the stimulatory and antiandrogenic actions of 17?-estradiol on the growth of androgen-sensitive Shionogi mammary carcinoma cells in culture. Endocrinology, 123: 1418-1424. | Prostate Cancer | 1988 |
| 219. Luthy, I.A., Bégin, D.J., Labrie, F. (1988) Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J. Steroid Biochem., 31: 845-852. | Prostate Cancer | 1988 |
| 220. Marchetti, B., Labrie, F. (1988) Characteristics of Flutamide action on prostatic and testicular functions in the rat. J. Steroid Biochem., 29: 691-698. | Prostate Cancer | 1988 |
| 221. Marchetti, B., Poulin, R., Plante, M., Labrie, F. (1988) Castration levels of plasma testosterone have potent stimulatory effects on androgen-sensitive parameters in the rat prostate. J. Steroid Biochem., 31: 411-419. | Prostate Cancer | 1988 |
| 222. Moorjani, S., Dupont, A., Labrie, F., Lupien, P.J., Gagné, C., Brun, D., Giguère, M., Bélanger, A., Cusan, L. (1988) Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen and combination treatment with LHRH agonist and Flutamide. J. Clin. Endocrinol. Metab., 66: 314-322. | Prostate Cancer | 1988 |
| 223. Pelletier, G., Labrie, C., Simard, J., Duval, M., Martinoli, M.G., Zhao, H., Labrie, F. (1988) Effects of sex steroids on regulation of the levels of C1 peptide of rat prostatic steroid-binding protein mRNA evaluated by in situ hybridization. J. Mol. Endocrinol., 1: 213-223. | Prostate Cancer | 1988 |
| 224. Plante, M., Lapointe, S., Labrie, F. (1988) Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice. J. Steroid Biochem., 31: 61-64. | Prostate Cancer | 1988 |
| 225. Rousseau, L., Dupont, A., Labrie, F., Couture, M. (1988) Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen Flutamide with medical (LHRH agonist) or surgical castration. Arch. Sex. Behav., 17: 87-98. | Prostate Cancer | 1988 |
| 226. Rousseau, L., Dupont, A., Labrie, F., Couture, M. (1988) Sexuality and antihormonal therapy in prostate cancer, in: Eicher, W. et Kockott, G., eds: Sexology, Berlin, Springer-Verlag, pp 290-303. | Prostate Cancer | 1988 |
| 227. Simard, J., Labrie, C., Hubert, J.-F., Labrie, F. (1988) Modulation by sex steroids and [D-Trp6, des-Gly-NH210]LHRH ethylamide of a subunit and LH? mRNA levels in the rat anterior pituitary gland. Mol. Endocrinol., 2: 775-784. | Prostate Cancer | 1988 |
| 228. St-Arnaud, R., Poyet, P., Walker, P., Labrie, F. (1988) Androgens modulate epidermal growth factor receptor levels in the rat ventral prostate. Mol. Cell. Endocrinol., 56: 21-27. | Prostate Cancer | 1988 |
| 229. Brochu, M., Bélanger, A., Dupont, A., Cusan, L., Labrie, F. (1987) Effects of Flutamide and aminoglutethimide on plasma 5?-reduced steroid glucuronide concentrations in castrated patients with cancer of the prostate. J. Steroid Biochem., 28: 619-622. | Prostate Cancer | 1987 |
| 230. Dubé, D., Assaf, A., Pelletier, G., Labrie, F. (1987) Morphological study of the effects of an GnRH agonist on the canine testis after 4 months of treatment and recovery. Acta Endocrinol. (Copenh.), 116: 413-417. | Prostate Cancer | 1987 |
| 231. Dubé, D., Pelletier, G., Labrie, F. (1987) Morphological studies of the canine pituitary LH cells after long-term treatment with the LHRH agonist [D-Trp6]LHRH ethylamide. Endocrinology, 120: 589-594. | Prostate Cancer | 1987 |
| 232. Labrie, C., Cusan, L., Plante, M., Lapointe, S., Labrie, F. (1987) Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer. J. Steroid Biochem., 28: 379-384. | Prostate Cancer | 1987 |
| 233. Labrie, F. (1987) Tratamiento del cancer de prostata mediante bloqueo hormonal completo, in: Carcinoma de Prostata: Avances en el Tratamiento Hormonal Patrocinado por la Asociacion Espanola de Urologia Barcelona, pp 61-67. | Prostate Cancer | 1987 |
| 234. Labrie, F., Dupont, A., Bélanger, A. (1987) LHRH agonists and antiandrogens in prostate cancer, in: Catalona, W.J. et Ratliff, T.L., eds: Genitourinary Cancer, Boston, Martinus Nijhoff Publishing, pp 157-200. | Prostate Cancer | 1987 |
| 235. Labrie, F., Dupont, A., Bélanger, A., Cusan, L., Giguère, M., Lacourcière, Y., Luthy, I., Bégin, D., Labrie, C., Simard, J., Monfette, G., Emond, J. (1987) Combination therapy in stage C and D prostatic cancer: rationale and 5-year clinical experience, in: Poste, G. et Fidler, I.J., eds: Cancer and Metastatic Reviews, Boston, Martinus Nijhoff Publishing, pp 615-636. | Prostate Cancer | 1987 |
| 236. Labrie, F., Dupont, A., Bélanger, A., Emond, J., Monfette, G., Luthy, I., Simard, J., Lachance, R. (1987) Flutamide in combination with castration (surgical or medical) is the standard treatment in advanced prostate cancer. J. Drug Develop., 1: 34-51. | Prostate Cancer | 1987 |
| 237. Labrie, F., Dupont, A., Bélanger, A., Giguère, M., Borsanyi, J.P., Bergeron, N., Lacourcière, Y., Emond, J., Monfette, G., Lachance, R. (1987) Combination therapy with Flutamide and castration in prostate cancer: four years of experience, in: D'Agata, R. et Chrousos, G.P., eds: Recent Advances in Adrenal Regulation and Function, New York, Raven Press, pp 209-221. | Prostate Cancer | 1987 |
| 238. Labrie, F., Dupont, A., Bélanger, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Emond, J., Monfette, G. (1987) Combined blockade with a pure antiandrogen (Flutamide) should be used without interruption in all patients with previously untreated or treated advanved prostate cancer, in: Beaulieu, E.E., Lacobelli, S. et McGuire, W.L., eds: Endocrinology and Malignancy - Basic and Clinical Issues. Proc. First International Congress on Cancer and Hormones, London, The Parthenon Publishing Group, pp 348-360. | Prostate Cancer | 1987 |
| 239. Labrie, F., Dupont, A., Bélanger, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Emond, J., Monfette, G., Lachance, R. (1987) Combination therapy with Flutamide and castration (LHRH agonist or orchiectomy): the minimal endocrine therapy in prostate cancer, in: McCann, S.M. et Weiner, R., eds: Integrative Neuroendocrinology: Molecular Cellular and Clinical Aspects, S. Karger, A.G. Basel, pp 220-234. | Prostate Cancer | 1987 |
| 240. Labrie, F., Dupont, A., Bélanger, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Emond, J., Monfette, G., Lachance, R. (1987) The importance of combination therapy with Flutamide and castration (LHRH agonist or orchiectomy) in previously untreated as well as previously treated patients with advanced prostate cancer, in: Klijn, J.G.M., Paridaens, R. et Foekens, J.A., eds: Hormonal Manipulation of Cancer: Peptides growth factors and new (anti)-steroidal agents. Monograph Series of the Europea, New York, Raven Press, pp 291-300. | Prostate Cancer | 1987 |
| 241. Labrie, F., Dupont, A., Bélanger, A., Lachance, R. (1987) Flutamide eliminates the risk of disease flare in prostate cancer patients treated with an LHRH agonist. J. Urol., 138: 804-806. | Prostate Cancer | 1987 |
| 242. Labrie, F., Dupont, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Bélanger, A., Lachance, R., Emond, J., Monfette, G., Lachance, R. (1987) Combination therapy with Flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients. J. Steroid Biochem., 27: 525-532. | Prostate Cancer | 1987 |
| 243. Labrie, F., Luthy, I., Veilleux, R., Simard, J., Bélanger, A., Dupont, A. (1987) New concepts on the androgen sensitivity of prostate cancer, in: Murphy, G.P., Khoury, S., Kuss, R., Chatelain, C. et Denis, L., eds: Progress in Clinical and Biological Research. Prostate cancer Part A: Research. Endocrine treatment and histopathology, pp 145-172. | Prostate Cancer | 1987 |
| 244. Labrie, F., Poulin, R., Simard, J., Hubert, J.F., Spinola, P., Marchetti, B. (1987) Adrenal steroids exert potent estrogen action in both normal and cancer tissue, in: Klijn, J.G.M., Paridaens, R. et Foekens, J.A., eds: Hormonal Manipulation of Cancer: Peptides Growth Factors and New (Anti-) Steroidal Agents. Monograph Series of the European Organization for Research on Treatment of Cancer, New York, Raven Press, pp 7-16. | Prostate Cancer | 1987 |
| 245. Luthy, I., Labrie, F. (1987) Development of androgen resistance in mouse mammary tumor cells can be prevented by the antiandrogen flutamide. Prostate, 10: 89-94. | Prostate Cancer | 1987 |
| 246. Moorjani, S., Dupont, A., Labrie, F., Lupien, P.J., Brun, D., Gagné, C., Giguère, M., Bélanger, A. (1987) Increase in plasma high density lipoprotein concentration following complete androgen blockage in men with prostate cancer. Metabolism, 36: 244-250. | Prostate Cancer | 1987 |
| 247. Soret, J.Y., Verine, J.L., Daver, A., Labrie, F. (1987) Comparative results of the variations in intraprostatic androgen levels and androgen receptors following pulpectomy with or without an antiandrogen (Flutamide) in the treatment of advanced prostate cancer, in: Murphy, G.P., Khoury, S., Kreiss, R., Chatelain, C. et Denis, L., eds: Prostate Cancer Research, Endocrine Treatment and Histopathology. Progress in Clinical and Biological Research, New York, Alan R. Liss Inc., pp 77. | Prostate Cancer | 1987 |
| 248. Soret, Y., Verine, J.L., Daver, A., Labrie, F. (1987) Levels of intraprostatic androgen receptors and intraprostatic testosterone following orchiectomy with or without addition of an antiandrogen (Flutamide) in the treatment of advanced prostatic cancer. J. Drug Dev., 1: 23-25. | Prostate Cancer | 1987 |
| 249. Dubé, D., Poyet, P., Pelletier, G., Labrie, F. (1986) Radioautographic localization of ?-adrenergic receptors in the rat ventral prostate. J. Androl., 7: 169-174. | Prostate Cancer | 1986 |
| 250. Harnois, C., Malenfant, M., Dupont, A., Labrie, F. (1986) Ocular toxicity of Anandron in patients treated for prostatic cancer. Br. J. Ophthalmol., 70: 471-473. | Prostate Cancer | 1986 |
| 251. Labrie, F., Bélanger, A., Dupont, A., Emond, J., Lacourcière, Y., Monfette, G. (1986) Cancers évolués de la prostate: traitement par l'association d'un agoniste de la LHRH et d'un antiandrogène pur. J. Int. Med., 66: 367-368. | Prostate Cancer | 1986 |
| 252. Labrie, F., Dupont, A., Bélanger, A. (1986) Blocco totale degli androgeni nel trattamento del cancro della prostata. Essex Oncologia, 3-47. | Prostate Cancer | 1986 |